Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...
Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...
Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...
Elevidys offers a one-shot therapy for the disease, with a price tag of $3.2 million, whereas other drugs to treat DMD, including Sarepta’s own exon-skipping range for patients with specific ...
The cuts hit the FDA’s medical device center particularly hard, impacting product reviewers and researchers of AI-enabled ...
We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...
The recent data from Sarepta’s Elevidys Phase III trial demonstrated significant improvements in primary and functional endpoints, which establishes the treatment’s efficacy and safety.
Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) will be an option for many more patients in the US after the FDA expanded the breadth of its approved labelling. Elevidys ...
Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...
Sarepta Therapeutics ... of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory ...
These projections underscore the market's confidence in Sarepta's ability to capitalize on its current momentum. Elevidys, Sarepta's gene therapy for DMD, has emerged as the company's primary growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results